Trisenox
(arsenic trioxide)ApprovedSmall molecule
Arsenic trioxide is used to treat certain types of leukemia (blood cancer), particularly acute promyelocytic leukemia. It works by causing cancer cells to die and helping the body's immune system fight the disease.[2] Trisenox is currently approved and in use across 50 indications[4].[1]
Trisenox is one of 1000 small molecule programs targeting Glioma. It is currently in Approved.
50
Indications
115
Total Trials
11
Active Trials
999
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 50 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Trisenox
CCephalon
Approved
Tykerb
GSKPreclinical
Halaven
EisaiPreclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Prolia
AmgenPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Megace
Bristol-Myers SquibbPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Lexiscan
AstellasPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Promyelocytic Leukemia20 trials
Show 17 more trials
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT02899169·110 enrolled
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
Active, not recruiting·—·N/A·NCT07187505·28 enrolled
Multiple Myeloma10 trials
Show 7 more trials
Arsenic Trioxide10 trials
Show 7 more trials
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT01428128·50 enrolled
Myelodysplastic Syndromes8 trials
Show 5 more trials
Acute Myeloid Leukemia7 trials
Show 4 more trials
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
Enrolling by invitation·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT03031249·80 enrolled
42 more indications
Leukemia5 trials
Chronic Myelogenous Leukemia4 trials
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Terminated·—·Phase 1·NCT01397734·7 enrolled
Show 1 more trial
Neuroblastoma3 trials
Myelodysplastic Syndrome3 trials
Malignant Glioma3 trials
Acute Lymphoblastic Leukemia2 trials
Glioma2 trials
Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00095771·36 enrolled
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
Completed·—·Phase 1·NCT00720564·18 enrolled
Hematologic Cancer2 trials
Myelofibrosis2 trials
Hepatocellular Carcinoma2 trials
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Unknown status·—·Phase 2·NCT02956772·190 enrolled
Refractory Solid Tumors1 trial
Myeloproliferative Disorder1 trial
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Completed·—·Phase 2·NCT00274820·15 enrolled
Patients With Advanced Solid Tumors1 trial
Pancreatic Cancer1 trial
Acute Leukemia1 trial
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Unknown status·—·Phase 2·NCT00003885·60 enrolled
Colorectal Cancer1 trial
Metastatic Melanoma1 trial
Prostate Cancer1 trial
Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
Completed·—·Phase 2·NCT00004149·37 enrolled
Gastroesophageal Junction1 trial
Non-Small Cell Lung Cancer1 trial
Breast Cancer1 trial
Lymphoma1 trial
Pediatric Cancer1 trial
Cervical Cancer1 trial
Relapsed or Refractory1 trial
Chronic Myelomonocytic Leukemia1 trial
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial
Effectiveness1 trial
Chronic Lymphocytic Leukemia1 trial
Plasma Cell Leukemia1 trial
Acute Myeloid Leukaemia1 trial
Lung Cancer1 trial
Liver Cancer1 trial
Pancreatic Ductal Adenocarcinoma1 trial
Regulatory
FDA Approval Timeline[5]
Sep 25, 2000
TRISENOX
NDA NDA021248
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Trisenox drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for arsenic trioxide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]